An update on the molecular pathology of urinary bladder tumors

Yousef, Peter G; Gabril, Manal

doi:10.1016/j.prp.2017.11.003

Cited by 36 publications

(18 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Bladder cancer is the most common malignant cancer in genitourinary system, bladder urothelial carcinoma (BUC) is the most common classification of bladder cancer, which was called bladder transitional cell carcinoma (BTCC) previously 1. Chemotherapy is a major therapeutic method for BUC, including systemic and intravesical chemotherapy, which can effectively inhibit the progression of BUC and improve the prognosis of patients 2.…”

Section: Introductionmentioning

confidence: 99%

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2

Li¹,

Xie²,

Zhang³

2019

J. Cancer

View full text Add to dashboard Cite

Objective : Chemotherapy is a major therapeutic method for bladder urothelial carcinoma (BUC), which can effectively improve the prognosis of BUC patients, but the chemoresistance often leads to chemotherapy failure. This study will research the regulatory roles and molecular mechanism of miR-101-3p in BUC chemoresistance. Materials and Methods : The quantitative real-time PCR was used to detect the expression of miRNA-101-3p and EZH2. The proliferation and chemoresistance were analyzed by CCK8 assay. Luciferase reporter assay was used to verify the combination between miR-101-3p and EZH2. Protein expression was detected by Western blotting. Flow cytometry was used to examine apoptosis rate. Results : The miR-101-3p expression was down-regulated in cisplatin (CDDP) resistant BUC cell line (T24/CDDP) and tissues, and was positively related to sensitivity of BUC to CDDP. In T24/CDDP cells, the up-regulation of miR-101-3p decreased the half maximal inhibitory concentration (IC50) to CDDP, depressed the expression of MRP1 protein, promote the CDDP-induced cytotoxicity, and advanced CDDP sensitivity. A series of in vitro experiments certified the EZH2 gene was a target gene of miR-101-3p, including luciferase reporter assay, western blotting and so on. Up-regulation of EZH2 largely reversed the regulatory effects of miR-101-3p enhancement on CDDP sensitivity in T24/CDDP cells. Conclusion : The expression of miR-101-3p is positively related to CDDP sensitivity of BUC, miR-101-3p advances sensitivity of BUC to CDDP through targeted silencing EZH2.

show abstract

Section: Introductionmentioning

confidence: 99%

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2

Li¹,

Xie²,

Zhang³

2019

J. Cancer

View full text Add to dashboard Cite

show abstract

“…They also have higher sensitivity than urine cytology but tend to be less specific and many suffer from variable performance [16][17][18] (Table 1). In addition, they have a lower sensitivity than white light cystoscopy for lower grade tumours (30-60%), with specificity ranging from 60% to 90%, and false-positive results in patients with inflammatory conditions [19]. The sensitivity and specificity values reported (Table 1) are highly dependent upon the clinical setting of the studies and discrepancy, therefore, arises from differences in patient cohort (selection criteria and size, tumour grades examined) and study design (primary or recurrent tumours; initial diagnosis or surveillance).…”

Section: Figurementioning

confidence: 99%

Shedding Light on Bladder Cancer Diagnosis in Urine

Chan

Gleadle

et al. 2020

Diagnostics

View full text Add to dashboard Cite

Blue light cystoscopy (BLC) is the most recent clinical approach in the detection and diagnosis of bladder cancer, a common type of cancer with a high rate of recurrence. Representing a significant advance over previous approaches, this photodynamic diagnostic technique uses a photosensitiser prodrug as an adjunct to white light cystoscopy to enhance the in vivo detection of malignant tissues in the bladder based on their distinctive fluorescence. Whilst it does improve detection rates, BLC remains an invasive and costly procedure. Meanwhile, a variety of noninvasive urine detection methods and related microdevices have been developed, none of which have yet entered routine clinical use due to unsatisfactory sensitivity. Following a brief description of the current approaches and their limitations, we provide here a systematic review of a newer niche research aiming to develop a noninvasive adaptation of photodynamic diagnosis. The research to date surrounding the ex situ use of photosensitiser prodrugs for urinary diagnosis of bladder cancer is also discussed.

show abstract

“…Muscle invasive urothelial carcinoma (MIUC) is a potentially lethal cancer with a 5-year relative survival rate ranges from less than 50% for stage II to less than 5% for stage IV (Flannery et al, 2018;Yousef and Gabril, 2018). Prognosis of MIUC is related to various pathological and clinical parameters and the most powerful prognostic factor is the pathological stage.…”

Section: Prognostic Value Of C-myc Immunohistochemical Expression In mentioning

confidence: 99%

Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study

Elwy

Elsaba

Elzaher

et al. 2019

Asian Pac J Cancer Prev

View full text Add to dashboard Cite

Objective: This study aimed to investigate the immunohistochemical expression of c-Myc in muscle invasive urothelial carcinoma (MIUC) of the urinary bladder and to evaluate the correlation of c-Myc expression with different clinicopathological parameters and outcome, including a relatively new histopathological tumor characteristic that is the growth pattern of tumor invasion. Methods: A total of 66 formalin-fixed and paraffin-embedded sections of MIUC obtained from radical cystectomy specimens were enrolled. The sections were stained with c-Myc antibody using immunohistochemistry technique. Results: Tumor cells showed variability in nuclear c-Myc expression according to the growth pattern of invasion. The median H-score of nuclear expression of infiltrative pattern was significantly higher than that of non-infiltrative pattern (p<0.001). Nuclear expression of c-Myc in tumor tissue had a significant association with poor prognostic factors (sarcomatoid variant (p<0.001), perineural invasion (p=0.037), lymphovascular invasion (p<0.001), lymph node metastasis (p<0.001), distant metastasis (p=0.042) and advanced stage grouping (p=0.001). Kaplan Meier survival analysis demonstrated that c-Myc expression could not be significantly correlated with overall survival or disease free survival rates. Conclusion: Nuclear c-Myc seems to have a prominent role in epithelial to mesenchymal transition with consequential in tumor progression and metastasis, while it is not as much useful to predict the clinical behavior of patients with MIUC.

show abstract

An update on the molecular pathology of urinary bladder tumors

Cited by 36 publications

References 49 publications

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2

MicroRNA-101-3p advances cisplatin sensitivity in bladder urothelial carcinoma through targeted silencing EZH2

Shedding Light on Bladder Cancer Diagnosis in Urine

Prognostic Value of c-Myc Immunohistochemical Expression in Muscle Invasive Urothelial Carcinoma of the Urinary Bladder: A Retrospective Study

Contact Info

Product

Resources

About